FDA Approved New PAH Drug from Actelion

ph_fda

According to a recent announcement, the United States Food and Drug Administration (FDA) approved Actelion Pharmaceuticals’ Uptravi (selexipag) tablets for the treatment of adult patients with pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization, under orphan drug designation.

PAH is a life-threatening disease characterized by high blood pressure and abnormal constriction of the pulmonary artery. The condition causes the heart to work faster and elevates blood pressure in arteries within the lungs, potentially causing fatal heart failure and other, less serious, complications and disturbances in quality of life.

 

Read more about it: http://bit.ly/1Jrfx5F

Leave a Comment

Your email address will not be published. Required fields are marked *